老年医学与保健2013，Vol.19Issue(1)：31-33,3.DOI:10.3969/j.issn.1008-8296.2013-01-10
地西他滨联合小剂量化疗治疗老年中高危骨髓增生异常综合征及急性髓系白血病的临床观察
Clinical study of CAG regimen combined Decitabine in treatment of elderly patients with moderate and high risk myelodysplastic syndrome and acute myeloid leukemia
摘要
Abstract
Objective To observe the clinical efficacy and adverse events of treatment for elderly patients with moderate and high-risk myelodysplastic syndrome (MDS) and acute myelocytic leukemia (AMD with Decitabine (25mg/d, d1-3) combined with CAG (G-CSF300ug/d, d4-13; aclarubicin10mg/d, d4,6,8,10,12; Ara-C25mg/d, d4-13) regimen. Methods Decitabine combined with CAG regimen were used to treat 10 elderly patients with MDS and AML. The outcome was evaluated after 1 course of treatment. Results For ten patients, 3/10(30%) achieved completely remission (CR), 4/10 (40%) marrow completely remission (mCR), 1/10 (10%) partial remission (PR). The overall response rate was 80%. Most patients can withstand adverse reactions occurred mainly for the arrest of bone marrow. Conclusion In older patients, medium and high-risk MDS and AML treated with Decitabine combined with CAG regimen is safe and effective.关键词
骨髓增生异常综合征/急性髓细胞白血病/地西他滨/CAG方案Key words
Myelodysplastic syndrome/ Acute myelocytic leukemia/ Decitabine/ CAG regimen分类
医药卫生引用本文复制引用
徐瑜,沙颖豪,谢彦晖..地西他滨联合小剂量化疗治疗老年中高危骨髓增生异常综合征及急性髓系白血病的临床观察[J].老年医学与保健,2013,19(1):31-33,3.
